Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide

Arthritis Care and Research

Volumn 63, Issue 3, 2011, Pages 351-357

  Dall'Era, Maria ^a   Stone, David ^b   Levesque, Victoria ^c   Cisternas, Miriam ^d   Wofsy, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Training in Early Abortion for Comprehensive Healthcare   (United States)

^c Vifor (International) Inc   (Switzerland)

^d MGC Data Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; AUTOANTIBODY; DNA; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PROTEINURIA; RISK; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG PULSE THERAPY; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; METABOLISM; MULTICENTER STUDY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; TIME; UNITED STATES;

ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; COMPLEMENT C3; COMPLEMENT C4; CYCLOPHOSPHAMIDE; DNA; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; KIDNEY; LOGISTIC MODELS; LUPUS NEPHRITIS; MALE; MYCOPHENOLIC ACID; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROTEINURIA; PULSE THERAPY, DRUG; SAN FRANCISCO; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857873453     PISSN: 00043591     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.20397     Document Type: Article

References (11)

1. Faurschou M, Dreyer L, Kamper AL, Starklint H, Jacobsen S. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res (Hoboken) 2010;62:873-80.
2. Sinclair A, Appel G, Dooley MA, Ginzler E, Isenberg D, Jayne D, et al. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 2007;16:972-80.
3. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isengerg D, Jayne D, et al. Mycophenolate mofetil versus cyclophospha-mide for the induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
4. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010;49:128-40.
5. SAS 9.2 help and documentation. Cary (NC): SAS Institute; 2008.
6. Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010;77:152-60.
7. Levey AS, Lan SP, Corwin HL, Kasinath BS, Lachin J, Neilson EG, et al. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study: results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med 1992;116:114-23.
8. Fraenkel L, MacKenzie T, Joseph L, Kashgarian M, Hayslett JP, Esdaile JM. Response to treatment as a predictor of long term outcome in patients with lupus nephritis. J Rheumatol 1994;21:2052-7. (Pubitemid 24352350)
9. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido ER, Danieli MG, et al. Early response to immuno-suppressive therapy predicts good renal outcome in lupus nephritis: lessons from long term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50: 3934-40. (Pubitemid 39643941)
10. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Gar-rido ER, Danieli MG, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69:61-4.
11. Ioannides JP, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000;57:258-64. (Pubitemid 30227773)